GleamWall
中文EN

ONCY ONCOLYTICS BIOTECH INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1129928 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-639.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets228.7%
Debt / equity—
Current ratio0.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-145.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue———————
R&D expense$5.15M$4.26M$4.55M$3.52M$5.08M$1.92M$2.80M
SG&A expense$4.59M$5.12M$4.73M$5.97M$4.48M$2.73M$2.22M
Operating income-$9.74M-$9.38M-$9.28M-$9.49M-$9.56M-$4.65M-$5.02M
Pretax income-$9.72M-$9.34M—-$8.69M-$10.06M-$5.22M—
Income tax-$13,000$101,000—$199,000-$181,000$61,000—
Net income-$9.71M-$9.44M-$9.24M-$8.89M-$9.88M-$5.28M-$4.71M
EBITDA-$9.72M-$9.36M-$9.27M-$9.47M-$9.55M-$4.63M-$5.00M
EPS (basic)-0.08-0.08-0.08—-0.10-0.06-0.06
EPS (diluted)-0.08-0.08-0.08—-0.10-0.06-0.06
Weighted avg. shares (diluted)127.89M119.74M112.29M—101.32M91.00M84.63M
Balance sheet
Cash & equivalents$2.43M$4.12M$5.49M$5.20M$8.87M$10.72M$10.64M
Current assets$5.27M$7.07M$7.49M$6.84M———
PP&E, net$193,000$202,000$218,000$228,000———
Total assets$5.83M$7.67M$8.16M$7.58M———
Current liabilities$5.92M$5.22M$5.42M$6.10M———
Total liabilities$13.34M$13.84M$13.29M$11.38M———
Shareholders' equity-$7.50M-$6.17M-$5.13M-$3.80M-$272,000$3.70M$3.73M
Shares outstanding132.21M124.64M116.13M108.02M———
Cash flow statement
Operating cash flow-$6.92M-$8.14M-$7.29M-$6.43M-$4.84M-$4.11M-$4.73M
Capital expenditure$7,000$0$6,000$1,000$4,000$0$1,000
Free cash flow-$6.92M-$8.14M-$7.30M-$6.43M-$4.85M-$4.11M-$4.73M
Investing cash flow-$7,000$0-$6,000-$1,000-$4,000$0-$1,000
Financing cash flow$5.24M$6.77M$7.61M$2.75M$3.09M$4.09M$4.18M
Depreciation & amortization$17,000$15,000$16,000$16,000$17,000$18,000$19,000
Stock-based compensation$2.03M$2.44M$2.30M$985,000$2.57M$362,000$845,000

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.